A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate
the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to Remicade in
subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX)
therapy.